What is it? Why is it important?

“Critical to Quality” (CtoQ) factors are identified aspects that stand out as being critical to the quality of a planned study.

 

Identifying CtoQ factors is important in order to instrument a “Quality by Design” (QbyD) approach to a study.

 

As studies vary greatly in scope, complexity, and budget, identifying CtoQ factors, and potential risks associated with these factors, are crucial to:

  • Protect study participants (e.g. participant rights and safety)
  • Focus on risks that are critical to achieving study objectives, and answering the study research question (e.g. study outcome/endpoint)
  • Provide credible and scientifically valuable research results
  • Have confidence in ensuing study interpretation and decision(s) taken (e.g. publishing)

 

Once CtoQ factors are identified, risks threatening their integrity are identified and decisions are made whether to accept or mitigate risks (i.e. based on risk probability, detectability and impact).

More

In an ongoing (IMP/IMD) study, research progresses and investigational product uncertainties may increase (e.g. safety, efficacy). Thus, CtoQ factors and risks threatening their integrity must be identified and assessed on an ongoing basis during study conduct, analysis, and reporting.

What do I need to do?

As a SP-INV during study design development:

 

At study planning, establish a framework to be used during study conduct, analysis, and reporting on how to:

  • Monitor the integrity of CtoQ factors
  • Identify and control risks to CtoQ factors (i.e. requirement for risk control-measure adjustments or the identification of new / unanticipated risks)
  • Assess the efficacy and applicability of risk control-measures
  • Retain oversight of CtoQ factors and their management

 

Where can I get help?

Your local Research Support Centre can assist you with experienced staff regarding this topic

  • Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch

  • Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch

  • Bern, Department of Clinical Research (DCR), dcr.unibe.ch

  • Geneva, Clinical Research Center (CRC), crc.hug.ch

  • Lausanne, Clinical Research Center (CRC), chuv.ch

  • St. Gallen, Clinical Trials Unit (CTU), h-och.ch

  • Zürich, Clinical Trials Center (CTC), usz.ch

References

ICH GCP E6(R3) – see in particular ICH GCP principles and guidelines

  • Main principle: Quality by design should be implemented to identify factors critical to trial quality
  • Principle 6. Quality should be built into the scientific, operational design, and conduct of the trial
  • 3.11.4.3 Monitoring plan and CtoQ
  • 6.2 Factors critical to quality
  • 7.3 Management of CtoQ factors

ICH E8(R1) – see in particular guidelines

  • 2.2 Scientific approach in clinical study design
  • 3. Designing quality into clinical studies
  • 3.1 Quality by design of clinical studies
  • 3.2 Critical to quality factors
  • 3.3 Approach to identify CtoQ factors
  • 5. Design elements and data sources for clinical studies
Abbreviations
  • CtoQ – Critical to Quality
  • CTU – Clinical Trials Unit
  • ICH – International Council for Harmonisation
  • ICH GCP – International Council for Harmonisation Good Clinical Practice
  • IMP/IMD – Investigational Medicinal Product / Investigational Medical Device
  • Medicinal Product
  • QbyD - Quality by Design
  • SP-INV – Sponsor-Investigator
Basic ↦ Quality and Risk ↦ Quality Requirements ↦ Critical to Quality
Study
Basic

Provides some background knowledge and basic definitions

Basic Monitoring
Concept

Starts with a study idea

Ends after having assessed and evaluated study feasibility

Concept Statistic Methodology
Concept Drug or Device
Development

Starts with confidence that the study is feasible

Ends after having received ethics and regulatory approval

Development Drug or Device
Set-Up

Starts with ethics and regulatory approval

Ends after successful study initiation

Set-Up Ethics and Laws
Set-Up Statistic Methodology
Set-Up Quality and Risk
Set-Up Drug or Device
Conduct

Starts with participant recruitment

Ends after the last participant has completed the last study visit

Conduct Statistic Methodology
Conduct Drug or Device
Completion

Starts with last study visit completed

Ends after study publication and archiving

Completion Drug or Device
Current Path (click to copy): Basic ↦ Quality and Risk ↦ Quality Requirements ↦ Critical to Quality